相关实验视频

Updated: Jul 7, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

瑞图西马布加贝利穆马布或特利塔西塞普在耐火性狼性炎中的疗效

Yiting Chen^1,2,3,4, Nan Shi^1,2,3,4, Xin Lei^1,2,3,4

¹Kidney Disease Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Rheumatology (Oxford, England)

|December 25, 2023

概括

结合治疗与rituximab,其次是belimumab或telitacicept显示出治疗难治性狼性炎的前景. 这种方法在狼性炎患者中实现了显著的性缓解率和降低了疾病活性.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
免疫学免疫学免疫学
类风湿病学类风湿病学

背景情况:

狼性炎是系统性红斑狼 (SLE) 的严重并发症,涉及B细胞激活和自身抗体的产生.
目前针对B细胞的治疗包括rituximab,belimumab和telitacicept,这些药物可能具有协同效应.

研究的目的:

评估在患有难治性狼性炎的患者中,依次治疗rituximab,其次是belimumab或telitacicept的疗效和安全性.

主要方法:

一个回顾性,单中心研究包括25名耐火性狼性炎患者.
患者接受Rituximab治疗B细胞枯竭,随后接受贝利马布或telitacicept.
主要终点是经过至少12个月的随访后的性缓解率.

主要成果:

80%的患者实现了客观缓解,76%的患者实现了完全的反应.
利图西马布加特利塔西塞普组显示了100%的完整脏反应率.
平均SLEDAI-2K得分下降了60%,72%的患者减少或停止使用普得尼松.

结论:

序列式的rituximab,belimumab或telitacicept疗法在耐火性狼性炎中诱导缓解似乎有效.
组合疗法显示了可容忍的副作用,主要是免疫球蛋白缺乏和感染.

关键词:

贝利姆巴姆巴姆是什么意思这是一种狼性炎.耐火材料耐火材料耐火材料这就是Rituximab.泰利塔的接收方式

更多相关视频

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...